FibroBiologics (FBLG) Accounts Payables (2022 - 2026)

FibroBiologics (FBLG) has reported Accounts Payables for 5 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 1.11% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at $1.8 million (up 1.11% YoY), and the FY2025 full-year result was $945000.0, down 64.96% from the prior year.
• Accounts Payables advanced to $1.8 million in Q2 2026 per FBLG's latest filing, from $850000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $2.7 million in Q4 2024 and bottomed at $758000.0 in Q4 2022.
• Historically, Accounts Payables has averaged $1.3 million across 5 years, with a median of $1.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables jumped 90.5% in 2023, then sank 64.96% in 2025.
• Over 5 years, Accounts Payables stood at $758000.0 in 2022, then surged by 90.5% to $1.4 million in 2023, then soared by 86.77% to $2.7 million in 2024, then tumbled by 64.96% to $945000.0 in 2025, then surged by 92.7% to $1.8 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $1.8 million, $850000.0, and $945000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.